Börsennachrichten
Aktuelle Finanznachrichten · Aktualisiert Jul 24, 2026
Kestra Medical erhöhte Umsatz um 63%. Ein Fonds reduzierte um 351.000 Aktien
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Panelists agree that Kestra Medical's cash burn rate is a significant concern, with the company having around 18-20 months of …
Was über diesen Fonds’ größere Wette auf Lionsgate Studios bei einem 85% Aktienanstieg zu wissen ist
What to Know About This Fund’s Bigger Bet on Lionsgate Studios Amid an 85% Stock Surge
The panel is divided on Lionsgate's future, with some seeing it as a potential takeover target due to its content …
Warum dieser 'langweilige' Aktienkurs jetzt ein starker Kauf ist
Why This "Boring" Stock Is a Strong Buy Right Now
The panel's net takeaway is that Coca-Cola's current valuation (24x forward P/E) leaves little room for margin compression, and its …
Warum die Aktie von Charles Schwab am Freitag starker wurde
Why Charles Schwab Stock Bumped Higher on Friday
Panelists are neutral on Schwab, citing rate sensitivity and structural risks, while acknowledging potential ROE improvement from deposit normalization.
Diese Tech-Aktie hat geduldigen Anlegern seit 5 Jahren Geld eingebracht und ist immer noch günstig
This Tech Stock Has Printed Money for Patient Investors for 5 Years, and It's Still Cheap
Onto Innovation's growth prospects hinge on the successful ramp of the Dragonfly G5 platform and maintaining its large HBM backlog. …
Diese Reiseaktie ist um 38% gefallen, aber ein Fonds erhöhte seine Position um 24 Millionen Dollar
This Travel Stock Is Down 38%, but a Fund Just Increased Its Position by $24 Million
The panel generally expresses skepticism about TRIP's turnaround prospects, with concerns about the core hotel business's decay, lack of operating …
„Sie nahmen 20.000 £, die ich nicht schuldete“: Eltern von Fehlern bei der Kinderbetreuung betroffen
'They took £20,000 I didn't owe': Parents hit by child maintenance errors
The panel agrees that the Child Maintenance Service's (CMS) high appeal overturn rate and lack of transparency regarding the monetary …
Prognose: Diese Aktie könnte sich bis 2031 verdoppeln
Prediction: This Stock Could Double By 2031
Panelists agreed that Exelixis' valuation hinges on the success of zanzalintinib, with significant risks around its late-stage trials and patent …
Anwälte von Elon Musk und OpenAI legen ihre abschließenden Plädoyers in einem Prozess vor, der die Zukunft der KI prägen könnte
Lawyers for Elon Musk and OpenAI make their final case in a trial that could shape AI's future
The panel consensus is that the trial's outcome, while important, may not be the most significant risk factor for OpenAI's …
Bicara-Aktie steigt um 50%, und ein Biotech-Investor hat es zu einem 29%-igen Portfolio-Bet gemacht
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Omega Fund's 29% allocation to Bicara (BCAX) reflects high conviction in ficerafusp alfa's Phase 2/3 trial, but the extreme concentration …
Warum ein Fonds eine Position in Ziff Davis in Höhe von 9 Millionen US-Dollar eröffnete, während ein großer Geschäftsverkauf stattfindet
Why One Fund Opened a $9 Million Position in Ziff Davis Amid a Major Business Sale
The panel generally agrees that Ziff Davis' strategy to divest its Connectivity segment is a necessary move, but the success …
Demokraten kritisieren Trump wegen "Schlammtopf" in möglichem IRS-Rechtsstreitvergleich
Democrats blast Trump over 'slush fund' in possible IRS lawsuit settlement
The panel is divided on the proposed $1.7 billion settlement, with concerns raised about potential governance issues and market uncertainty, …